Heart Failure Drugs Market by Drug Class and Geography - Forecast and Analysis 2021-2025

***1. Executive Summary                         

***2. Market Landscape                            

               **2.1 Market ecosystem             

                              *Exhibit 01: Parent market

               **2.2: Market Characteristics     

                           *Exhibit 02: Market Characteristics

               **2.2 Value chain analysis           

                              *Exhibit 03: Value chain analysis: Pharmaceuticals

                              *2.2.1 Research and development (R&D) and drug discovery

                              *2.2.2 Integration and product development

                              *2.2.3 Manufacturing

                              *2.2.4 Outbound logistics

                              *2.2.5 Marketing and sales

                              *2.2.6 Support services

                              *2.2.7 Innovation

***3. Market Sizing                      

               **3.1 Market definition

                              *Exhibit 04: Offerings of vendors included in the market definition

               **3.2 Market segment analysis  

                              *Exhibit 05: Market segments

               **3.3 Market size 2020 

               **3.4 Market outlook: Forecast for 2020 - 2025 

                              *3.4.1 Estimating growth rates for emerging and high-growth markets

                              *3.4.2 Estimating growth rates for mature markets

                              *Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)

                              *Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

***4. Five Forces Analysis                         

               **4.1 Five Forces Summary         

                              *Exhibit 08: Five forces analysis 2021 & 2026

               **4.2 Bargaining power of buyers            

                              *Exhibit 09: Bargaining power of buyers

               **4.3 Bargaining power of suppliers        

                              *Exhibit 10: Bargaining power of suppliers

               **4.4 Threat of new entrants     

                              *Exhibit 11: Threat of new entrants

               **4.5 Threat of substitutes          

                              *Exhibit 12: Threat of substitutes

               **4.6 Threat of rivalry   

                              *Exhibit 13: Threat of rivalry

               **4.7 Market condition 

                              *Exhibit 14: Market condition - Five forces 2021

***5 Market Segmentation by Drug class                           

               **5.1 Market segments

                              *The segments covered in this chapter are:

• *Beta blockers
• *ARBs
• *ACE inhibitors
• *Others

                              *Exhibit 15: Drug class - Market share 2020-2025 (%)

               **5.2 Comparison by Drug class

                              *Exhibit 16: Comparison by Drug class

               **5.3 Beta blockers - Market size and forecast 2020-2025             

                              *Exhibit 17: Beta blockers - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 18: Beta blockers - Year-over-year growth 2020-2025 (%)

                              *Exhibit 19: Common beta blockers used for CVDs

               **5.4 ARBs - Market size and forecast 2020-2025             

                              *Exhibit 20: ARBs - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 21: ARBs - Year-over-year growth 2020-2025 (%)

               **5.5 ACE inhibitors - Market size and forecast 2020-2025            

                              *Exhibit 22: ACE inhibitors - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 23: ACE inhibitors - Year-over-year growth 2020-2025 (%)

               **5.6 Others - Market size and forecast 2020-2025          

                              *Exhibit 24: Others - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 25: Others - Year-over-year growth 2020-2025 (%)

               **5.7 Market opportunity by Drug class

                              *Exhibit 26: Market opportunity by Drug class

***6 Customer landscape                         

                              *Exhibit 27: Customer landscape

***7 Geographic Landscape                     

               **7.1 Geographic segmentation

                              *Exhibit 28: Market share by geography 2020-2025 (%)

               **7.2 Geographic comparison    

                              *Exhibit 29: Geographic comparison

               **7.3 North America - Market size and forecast 2020-2025          

                              *North America - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 31: North America - Year-over-year growth 2020-2025 (%)

               **7.4 Europe - Market size and forecast 2020-2025         

                              *Exhibit 32: Europe - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 33: Europe - Year-over-year growth 2020-2025 (%)

               **7.5 Asia - Market size and forecast 2020-2025

                              *Exhibit 34: Asia - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 35: Asia - Year-over-year growth 2020-2025 (%)

               **7.6 ROW - Market size and forecast 2020-2025             

                              *Exhibit 36: ROW - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 37: ROW - Year-over-year growth 2020-2025 (%)

               **7.7 Key leading countries        

                              *Exhibit 38: Key leading countries

               **7.8 Market opportunity by geography

                              *Exhibit 39: Market opportunity by geography

***8 Drivers, Challenges, and Trends                   

               **8.1 Market drivers      

                              *8.1.1 Rising geriatric population

                              *8.1.2 Increase in chronic diseases

                              *8.1.3 Sedentary lifestyle

               **8.2 Market challenges              

                              *8.2.1 Highly genericized market

                              *8.2.2 Side effects of drugs

                              *8.2.3 Stringent regulatory guidelines

                              *Exhibit 40: Impact of drivers and challenges

               **8.3 Market trends      

                              *8.3.1 Growing strategic alliances

                              *8.3.2 Investment inclination toward developing countries

                              *8.3.3 New drug development

***9. Vendor Landscape                            

               **10.1   Competitive scenario     

               **10.2   Vendor landscape           

                              *Exhibit 41: Vendor Landscape

               **10.3   Landscape disruption     

                              *Exhibit 42: Landscape disruption

               **10.4   Industry risks     

                              *Exhibit 43: Industry risks

***11.   Vendor Analysis                             

               **11.1   Vendors covered             

                              *Exhibit 44: Vendors covered

               **10.2 Market positioning of vendors   

                              *Exhibit 45: Market positioning of vendors

               **10.3 Amgen Inc.

                              *Exhibit 46: Amgen Inc. - Overview

                              *Exhibit 47: Amgen Inc. - Business segments

                              *Exhibit 48: Amgen Inc. - Key news

                              *Exhibit 49: Amgen Inc. - Key offerings

               **10.4 AstraZeneca Plc 

                              *Exhibit 50: AstraZeneca Plc - Overview

                              *Exhibit 51: AstraZeneca Plc - Product and service

                              *Exhibit 52: AstraZeneca Plc - Key offerings

               **10.5 Bayer AG             

                              *Exhibit 53: Bayer AG - Overview

                              *Exhibit 54: Bayer AG - Business segments

                              *Exhibit 55: Bayer AG - Key news

                              *Exhibit 56: Bayer AG - Key offerings

                              *Exhibit 57: Bayer AG - Segment focus

               ** 10.6 Bristol-Myers Squibb Co

                              *Exhibit 58: Bristol-Myers Squibb Co. - Overview

                              *Exhibit 59: Bristol-Myers Squibb Co. - Product and service

                              *Exhibit 60: Bristol-Myers Squibb Co. - Key offerings

               **10.7 Daiichi Sankyo Co. Ltd.   

                              *Exhibit 61: Daiichi Sankyo Co. Ltd. - Overview

                              *Exhibit 62: Daiichi Sankyo Co. Ltd. - Business segments

                              *Exhibit 63: Daiichi Sankyo Co. Ltd. - Key offerings

                              *Exhibit 64: Daiichi Sankyo Co. Ltd. - Segment focus

               **10.8 Eli Lilly and Co.  

                              *Exhibit 65: Eli Lilly and Co. - Overview

                              *Exhibit 66: Eli Lilly and Co. - Business segments

                              *Exhibit 67: Eli Lilly and Co. - Key news

                              *Exhibit 68: Eli Lilly and Co. - Key offerings

               **10.9 Exelixis Inc          

                              *Exhibit 69: Exelixis Inc. - Overview

                              *Exhibit 70: Exelixis Inc. - Business segments

                              *Exhibit 71: Exelixis Inc. - Key offerings

               **10.10 Gilead Sciences Inc.      

                              *Exhibit 72: Gilead Sciences Inc. - Overview

                              *Exhibit 73: Gilead Sciences Inc. - Product and service

                              *Exhibit 74: Gilead Sciences Inc. - Key offerings

               **10.11 Novartis AG      

                              *Exhibit 75: Novartis AG - Overview

                              *Exhibit 76: Novartis AG - Business segments

                              *Exhibit 77: Novartis AG - Key news

                              *Exhibit 78: Novartis AG - Key offerings

                              *Exhibit 79: Novartis AG - Segment focus

               **10.12 Pfizer Inc.          

                              *Exhibit 80: Pfizer Inc. - Overview

                              *Exhibit 81: Pfizer Inc. - Business segments

                              *Exhibit 82: Pfizer Inc. - Key news

                              *Exhibit 83: Pfizer Inc. - Key offerings

***12. Appendix                           

               **12.1 Scope of the report         

                              *12.1.1 ????Market definition

                              *12.1.2 ????Objectives

                              *12.1.3 ????Notes and caveats

               **12.2 Currency conversion rates for US$            

                              *Exhibit 84: ?Currency conversion rates for US$?

               **12.3 Research Methodology   

                              *Exhibit 85: ?Research Methodology

                              *Exhibit 86: ??Validation techniques employed for market sizing?

                              *Exhibit 87: ??Information sources

               **12.4 List of abbreviations